Innate Pharma SA (OTCMKTS:IPHYF – Get Free Report) was down 32.9% during trading on Friday. The stock traded as low as $1.5092 and last traded at $1.5092. 1,000 shares changed hands during mid-day trading, The stock had previously closed at $2.25.
Innate Pharma Stock Performance
The business has a 50-day simple moving average of $1.65 and a two-hundred day simple moving average of $1.65.
About Innate Pharma
Innate Pharma SA is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune mechanisms that can recognize and attack tumor cells. Its activities include drug discovery, clinical development and collaborations with pharmaceutical companies.
Innate Pharma’s pipeline has included antibody-based therapies designed to stimulate or direct immune responses against cancer.
Recommended Stories
- Five stocks we like better than Innate Pharma
- AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
- Time to Nibble on MCD Stock After it Enters Oversold Territory?
- McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
- Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
